Fintel reports that on October 31, 2025, HC Wainwright & Co. maintained coverage of Apellis Pharmaceuticals (NasdaqGS:APLS) with a Buy recommendation.
Analyst Price Forecast Suggests 86.70% Upside
As of October 29, 2025, the average one-year price target for Apellis Pharmaceuticals is $38.70/share. The forecasts range from a low of $18.18 to a high of $63.00. The average price target represents an increase of 86.70% from its latest reported closing price of $20.73 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Apellis Pharmaceuticals is 1,291MM, an increase of 27.02%. The projected annual non-GAAP EPS is -3.56.
What is the Fund Sentiment?
There are 479 funds or institutions reporting positions in Apellis Pharmaceuticals. This is an decrease of 4 owner(s) or 0.83% in the last quarter. Average portfolio weight of all funds dedicated to APLS is 0.12%, an increase of 14.25%. Total shares owned by institutions increased in the last three months by 5.59% to 141,770K shares. 
The put/call ratio of APLS is 0.18, indicating a bullish outlook.
What are Other Shareholders Doing?
Avoro Capital Advisors holds 12,222K shares representing 9.68% ownership of the company. No change in the last quarter.
EcoR1 Capital holds 11,896K shares representing 9.42% ownership of the company. No change in the last quarter.
Wellington Management Group Llp holds 8,977K shares representing 7.11% ownership of the company. In its prior filing, the firm reported owning 12,303K shares , representing a decrease of 37.05%. The firm decreased its portfolio allocation in APLS by 92.36% over the last quarter.
Deep Track Capital holds 7,000K shares representing 5.54% ownership of the company. In its prior filing, the firm reported owning 5,000K shares , representing an increase of 28.57%. The firm increased its portfolio allocation in APLS by 9.74% over the last quarter.
VGHCX - Vanguard Health Care Fund Investor Shares holds 6,243K shares representing 4.94% ownership of the company. In its prior filing, the firm reported owning 9,287K shares , representing a decrease of 48.76%. The firm decreased its portfolio allocation in APLS by 12.93% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
